Omar Ishrak - Medtronic PLC Chairman of the Board, Chief Executive Officer
MDT Stock | USD 82.29 0.91 1.12% |
Chairman
Mr. Omar Syed Ishrak, Ph.D., serves as Chairman of the Board, Chief Executive Officer of the Company. He was Chairman and Chief Executive Officer of the Company since January 2015 and of Medtronic, Inc. since June 2011. Prior to that, Mr. Ishrak served as President and Chief Executive Officer of GE Healthcare Systems, a division of GE Healthcare, from 2009 to 2011. Prior to that, Mr. Ishrak was President and Chief Executive Officer of GE Healthcare Clinical Systems from 2005 to 2008 and President and Chief Executive Officer of GE Healthcare Ultrasound and BMD from 1995 to 2004. since 2020.
Age | 63 |
Tenure | 4 years |
Address | 20 On Hatch, Dublin, Ireland, 2 |
Phone | 353 1 438 1700 |
Web | https://www.medtronic.com |
Medtronic PLC Management Efficiency
The company has Return on Asset of 0.0474 % which means that on every $100 spent on assets, it made $0.0474 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0726 %, implying that it generated $0.0726 on every 100 dollars invested. Medtronic PLC's management efficiency ratios could be used to measure how well Medtronic PLC manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.07 in 2024. Return On Capital Employed is likely to drop to 0.08 in 2024. Total Current Liabilities is likely to gain to about 11.3 B in 2024. Liabilities And Stockholders Equity is likely to gain to about 94.5 B in 2024Similar Executives
Found 1 records | CHAIRMAN Age | ||
Zackary Irani | Biomerica | 58 |
Management Performance
Return On Equity | 0.0726 | ||||
Return On Asset | 0.0474 |
Medtronic PLC Leadership Team
Elected by the shareholders, the Medtronic PLC's board of directors comprises two types of representatives: Medtronic PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medtronic. The board's role is to monitor Medtronic PLC's management team and ensure that shareholders' interests are well served. Medtronic PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medtronic PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
Brett Wall, Executive Vice President and President Restorative Therapies Group | ||
Jennifer Kirk, Chief Accounting Officer, Global Controller | ||
Bradley Lerman, Senior Vice President General Counsel, Corporate secretary | ||
Scott Donnelly, Lead Independent Director | ||
Kenneth Washington, Senior Officer | ||
Richard Anderson, Lead Independent Director | ||
Ryan Weispfenning, Vice President - Investor Relations | ||
Mark Ploof, Senior Services | ||
Sean Lennon, Chief Officer | ||
Hooman Hakami, Executive Vice President and Group President of the Medtronic Diabetes Group | ||
Elizabeth Nabel, Independent Director | ||
Richard Kuntz, Senior Vice President and Chief Scientific, Clinical and Regulatory Officer | ||
James Lenehan, Independent Director | ||
John Liddicoat, Executive Vice President and President Americas Region | ||
Robert White, Executive Vice President and President of Medtronic’s Minimally Invasive Therapies Group | ||
Kevin Lofton, Independent Director | ||
Craig Arnold, Independent Director | ||
Kendall Powell, Lead Independent Director | ||
Sally Saba, Chief Inclusion and Diversity Officer | ||
Denise OLeary, Independent Director | ||
Omar Ishrak, Chairman of the Board, Chief Executive Officer | ||
Brad Lerman, Senior Vice President General Counsel, Corporate secretary | ||
Ivan Fong, General VP | ||
Sean Salmon, Executive Vice President and President, Diabetes Operating Unit, President, Cardiovascular Portfolio | ||
Carol Surface, Chief Human Resource Officer, Senior Vice President | ||
Karen Parkhill, Chief Financial Officer, Executive Vice President | ||
Michael Leavitt, Independent Director | ||
Geoffrey Martha, Executive Vice President and President - Restorative Therapies Group | ||
Randall Hogan, Independent Director | ||
Andrea Goldsmith, Independent Director | ||
Robert Hoedt, Executive Vice President and President - EMEA Region | ||
MSc MD, Medical Scientific | ||
Michael Coyle, Executive Vice President, Group President - Cardiac and Vascular Group |
Medtronic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medtronic PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0726 | ||||
Return On Asset | 0.0474 | ||||
Profit Margin | 0.11 % | ||||
Operating Margin | 0.16 % | ||||
Current Valuation | 125.13 B | ||||
Shares Outstanding | 1.31 B | ||||
Shares Owned By Insiders | 0.10 % | ||||
Shares Owned By Institutions | 85.81 % | ||||
Number Of Shares Shorted | 14.03 M | ||||
Price To Earning | 20.44 X |
Pair Trading with Medtronic PLC
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medtronic PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medtronic PLC will appreciate offsetting losses from the drop in the long position's value.Moving against Medtronic Stock
0.54 | GCTK | GlucoTrack | PairCorr |
0.53 | DYNT | Dynatronics Fiscal Year End 26th of September 2024 | PairCorr |
The ability to find closely correlated positions to Medtronic PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medtronic PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medtronic PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medtronic PLC to buy it.
The correlation of Medtronic PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medtronic PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medtronic PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medtronic PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medtronic PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Medtronic Stock please use our How to Invest in Medtronic PLC guide.Note that the Medtronic PLC information on this page should be used as a complementary analysis to other Medtronic PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Medtronic Stock analysis
When running Medtronic PLC's price analysis, check to measure Medtronic PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medtronic PLC is operating at the current time. Most of Medtronic PLC's value examination focuses on studying past and present price action to predict the probability of Medtronic PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medtronic PLC's price. Additionally, you may evaluate how the addition of Medtronic PLC to your portfolios can decrease your overall portfolio volatility.
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |
Is Medtronic PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medtronic PLC. If investors know Medtronic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medtronic PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.44) | Dividend Share 2.76 | Revenue Per Share 24.376 | Quarterly Revenue Growth 0.005 | Return On Assets 0.0474 |
The market value of Medtronic PLC is measured differently than its book value, which is the value of Medtronic that is recorded on the company's balance sheet. Investors also form their own opinion of Medtronic PLC's value that differs from its market value or its book value, called intrinsic value, which is Medtronic PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medtronic PLC's market value can be influenced by many factors that don't directly affect Medtronic PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medtronic PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if Medtronic PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medtronic PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.